The DOI matches its Crossref record; 34 of the 37 references it cites were found in a registry or an index.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Open accessAbstract
Background Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.Methods In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.Findings Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.Interpretation Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.Funding Bristol-Myers Squibb.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Initial results demonstrated a 31% objective response rate and 69% demonstrated at least 12 weeks of stable disease [78].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [78]
In the citing paper
“The Checkmate-142 phase II study demonstrated the effectiveness of nivolumab in previously treated MSI-H mCRC patients [84].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Upon examining the subgroup analysis of this study, it was observed that patients without RAS or BRAF mutations achieved a 41% objective response rate with nivolumab. In comparison, the rate was 27% in RAS mutant patients.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [84]
In the citing paper
“Additionally, the efficacy of ICIs in phase II studies with dMMR/MSI and BRAFV600E tumors versus dMMR/MSI and BRAF wild type was similar [53,54,55,56].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Recently, a combination of nivolumab and ipilimumab, a CTLA-4 inhibitor, gained approval from the FDA for the treatment of previously treated MSI-H/dMMR mCRC [54,131].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“Nivolumab, an anti-PD1 monoclonal antibody (moAb), has been utilized since 1 August 2017, for MSI-H/dMMR mCRC, as evidenced by the CheckMate 142 study [54].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [54]
In the citing paper
“The CHECKMATE 142 study reported that Nivolumab could provide a durable response in patients with dMMR/MSI-H metastatic colorectal cancer, proposing Nivolumab as a new treatment option in these patients [117].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [117]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Cited by
Sorted by citations
Items 601–700 of 1,005
Cohen, R., Colle, R., Pudlarz, T., Heran, M., Duval, A., Svrcek, M., & André, T. (2021) · Cancers · doi:10.3390/cancers13051149 · Cited by 47
Self-citationYu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
TGFβ2 is a prognostic‐related biomarker and correlated with immune infiltrates in gastric cancer
Xiao, Z., Hu, L., Yang, L., Wang, S., Gao, Y., Zhu, Q., Yang, G., Huang, D., & Xu, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15164 · Cited by 47
Mola, S., Pandolfo, C., Sica, A., & Porta, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186866 · Cited by 48
Kavun, A., Veselovsky, E., Lebedeva, A., Belova, E., Kuznetsova, O. A., Yakushina, V. D., Grigoreva, T. V., Mileyko, V., Fedyanin, M. Y., & Ivanov, M. V. (2023) · Cancers · doi:10.3390/cancers15082288 · Cited by 52
Sun, G., Zhao, S., Fan, Z., Wang, Y., Liu, H., Cao, H., Sun, G., Huang, T., Cai, H., Pan, H., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02803-0 · Cited by 47
Fumet, J.-D., Isambert, N., Hervieu, A., Zanetta, S., Guion, J.-F., Hennequin, A., Rederstorff, E., Bertaut, A., & Ghiringhelli, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000375 · Cited by 47
Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral, L., Coutzac, C., Kannouche, P. L., & Chaput, N. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.08.007 · Cited by 48
Mechanisms of immunogenicity in colorectal cancer
Sillo, T. O., Beggs, A. D., Morton, D. G., & Middleton, G. (2019) · British journal of surgery · doi:10.1002/bjs.11204 · Cited by 49
Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab
Jacome, A. A. D. A., & Eng, C. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1680636 · Cited by 47
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer
Ducoin, K., Oger, R., Mutala, L. B., Deleine, C., Jouand, N., Desfrançois, J., Podevin, J., Duchalais, E., Cruard, J., Benlalam, H., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2046931 · Cited by 47
Pecci, F., Cantini, L., Bittoni, A., Lenci, E., Lupi, A., Crocetti, S., Giglio, E., Giampieri, R., & Berardi, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00870-z · Cited by 48
Chen, X., Li, J., Zhang, R., Zhang, Y., Wang, X., Leung, E. L., Ma, L., Wong, V. K. W., Liu, L., Neher, E., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12279 · Cited by 46
Zhang, B., Wang, C., Wu, H., Wang, F., Chai, Y., Hu, Y., Wang, B., Zhou, Y. L., Xia, R., Xu, R., et al. (2023) · 癌症：英文版 · doi:10.1002/cac2.12476 · Cited by 47
Marabelle, A., O’Malley, D. M., Hendifar, A. E., Ascierto, P. A., Motola‐Kuba, D., Penel, N., Cassier, P. A., Bariani, G. M., Jesus‐Acosta, A. D., Doi, T., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00894-y · Cited by 48
The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer
Carrillo, M. A., Zhen, A., & Kitchen, S. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00746 · Cited by 46
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 47
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
Fountzilas, E., Kurzrock, R., Vo, H. H., & Tsimberidou, A. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab067 · Cited by 44
Gong, L., Kwong, D. L., Dai, W., Wu, P., Wang, Y., Lee, A. W. M., & Guan, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.744889 · Cited by 45
Autophagy: A Versatile Player in the Progression of Colorectal Cancer and Drug Resistance
Manzoor, S., Muhammad, J. S., Maghazachi, A. A., & Hamid, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924290 · Cited by 45
Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
Paidi, S. K., Troncoso, J. R., Raj, P., Diaz, P. M., Ivers, J. D., Lee, D. E., Avaritt, N. L., Gies, A. J., Quick, C. M., Byrum, S. D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1438 · Cited by 46
Frailty and checkpoint inhibitor toxicity in older patients with melanoma
Bruijnen, C. P., Koldenhof, J. J., Verheijden, R. J., van den Bos, F., Emmelot‐Vonk, M. H., Witteveen, P. O., & Suijkerbuijk, K. P. M. (2022) · Cancer · doi:10.1002/cncr.34230 · Cited by 48
Xiao, B., Zhang, X., Cao, T., Li, D., Wu, J., Kong, L.-H., Tang, J., Han, K., Zhang, C.-Z., Mei, W.-J., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7060 · Cited by 46
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
Pan, Y., Shu, G., Fu, L., Huang, K., Zhou, X., Gui, C., Liu, H., Jin, X., Chen, M., Li, P., et al. (2023) · Advanced Science · doi:10.1002/advs.202206792 · Cited by 47
Moretto, R., Rossini, D., Catteau, A., Antoniotti, C., Giordano, M., Boccaccino, A., Ugolini, C., Proietti, A., Conca, V., Kassambara, A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006633 · Cited by 46
Self-citationParente, P., Grillo, F., Vanoli, A., Macciomei, M. C., Ambrosio, M. R., Scibetta, N., Filippi, E., Cataldo, I., Baron, L., Ingravallo, G., et al. (2023) · Digestive Diseases · doi:10.1159/000531003 · Cited by 45
The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategies
Wang, H., Tang, R., Ling, J., & Jia, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1494802 · Cited by 50
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
Clarke, J. M., George, D. J., Lisi, S., & Salama, A. K. S. (2018) · Targeted Oncology · doi:10.1007/s11523-017-0549-7 · Cited by 45
Response to PD1 inhibition in conventional chondrosarcoma
Wagner, M. J., Ricciotti, R. W., Mantilla, J. G., Loggers, E. T., Pollack, S. M., & Cranmer, L. D. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0413-z · Cited by 50
New therapies and insights into the changing landscape of colorectal cancer
Kopetz, S. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0100-z · Cited by 44
Self-citationCurrent Status of Immunotherapies for Treating Pancreatic Cancer
Wu, A. A., Jaffee, E. M., & Lee, V. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0811-5 · Cited by 47
Floudas, C. S., Brar, G. S., Mabry‐Hrones, D., Duffy, A. G., Wood, B. J., Levy, E. B., Krishnasamy, V. P., Fioravanti, S., Bonilla, C. M., Walker, M., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.06.004 · Cited by 47
Wang, C., Park, J., Ouyang, C., Longmate, J., Tajon, M., Chao, J., Lim, D. W., Sandhu, J. S., Yin, H. H., Pillai, R. K., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0924 · Cited by 45
Miyazaki, T., Ishikawa, E., Matsuda, M., Sugii, N., Kohzuki, H., Akutsu, H., Sakamoto, N., Takano, S., & Matsumura, A. (2020) · Brain Tumor Pathology · doi:10.1007/s10014-020-00357-z · Cited by 46
Benítez, J. C., Recondo, G., Rassy, E., & Mezquita, L. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03250-1 · Cited by 45
Şahin, İ. H., Goyal, S., Pumpalova, Y. S., Sonbol, M. B., Das, S., Haraldsdóttir, S., Ahn, D. H., Ciombor, K. K., Chen, Z., Draper, A., et al. (2021) · The Oncologist · doi:10.1002/onco.13741 · Cited by 45
B2M and JAK1/2–mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy
Zhang, C., Li, D., Xiao, B., Zhou, C., Jiang, W., Tang, J., Li, Y., Zhang, R., Han, K., Hou, Z., et al. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000417 · Cited by 44
Cheng, L., Chen, L., Shi, Y., Gu, W., Ding, W., Zheng, X. W., Liu, Y., Jiang, J., & Zheng, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01956-6 · Cited by 49
Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
Stein, A., Moehler, M. H., Trojan, J., Goekkurt, E., & Vogel, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.001 · Cited by 44
Lynch syndrome – cancer pathways, heterogeneity and immune escape
Seth, S., Ager, A., Arends, M. J., & Frayling, I. M. (2018) · The Journal of Pathology · doi:10.1002/path.5139 · Cited by 44
HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
Salvia, A. L., López-Gómez, V., & García‐Carbonero, R. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1555583 · Cited by 44
Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer
Rawla, P., Barsouk, A. A., Hadjinicolaou, A. V., & Barsouk, A. (2019) · Medical Sciences · doi:10.3390/medsci7080083 · Cited by 46
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin
Galaine, J., Turco, C., Vauchy, C., Royer, B., Mercier‐Letondal, P., Queiroz, L., Loyon, R., Mouget, V., Boidot, R., Laheurte, C., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32620 · Cited by 44
Chen, W., Li, G., Hu, Z.-N., Zhu, P., Zhang, B., & Ding, Z. (2019) · Medicine · doi:10.1097/md.0000000000017832 · Cited by 44
LAG-3 Expression Predicts Outcome in Stage II Colon Cancer
Agocs, G. R., Assarzadegan, N., Kirsch, R., Dawson, H., Galván, J. A., Lugli, A., Zlobec, I., & Berger, M. D. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080749 · Cited by 46
Cen, S., Liu, K., Zheng, Y., Shan, J., Jing, C., Gao, J., Pan, H., Bai, Z., & Liu, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705060 · Cited by 45
He, R., Lao, Y., Yu, W., Zhang, X., Jiang, M., & Zhu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.764618 · Cited by 46
Zhang, X., Yang, R., Wu, T., Cai, X., Li, G., Yu, K., Li, Y., Ding, R., Dong, C., Li, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.913483 · Cited by 44
Demisse, R., Damle, N., Kim, E. J.-H., Gong, J., Fakih, M., Eng, C., Oesterich, L. G., McKenny, M., Ji, J., Liu, J., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7558 · Cited by 43
Liu, Z., Lu, T., Wang, Y., Jiao, D., Li, Z., Wang, L., Liu, L., Guo, C., Zhao, Y., & Han, X. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16696 · Cited by 42
Immune checkpoint inhibitors in cervical cancer: Current status and research progress
Xie, Y., Kong, W., Zhao, X., Zhang, H., Luo, D., & Chen, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984896 · Cited by 45
Huang, L., Zhu, H., & Shi, Y. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01734-x · Cited by 48
Tesfaye, A. A., Kamgar, M., Azmi, A. S., & Philip, P. A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1417844 · Cited by 43
Bando, H., Okamoto, W., Fukui, T., Yamanaka, T., Akagi, K., & Yoshino, T. (2018) · Cancer Science · doi:10.1111/cas.13774 · Cited by 43
A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer
Ljubas, J., Ovesen, T., & Rusan, M. (2019) · Cancers · doi:10.3390/cancers11070943 · Cited by 43
Advances of immune checkpoints in colorectal cancer treatment
Jiao, Q., Ren, Y., Gabrie, A. N. A., Wang, Q., Wang, Y., Du, L., Liu, X., Wang, C., & Wang, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109745 · Cited by 48
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 44
Zhao, Y., Zhang, M., Pu, H., Guo, S., Zhang, S., & Wang, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.585961 · Cited by 41
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Arai, H., Elliott, A., Xiu, J., Wang, J., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Millstein, J., Sohal, D. P. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3635 · Cited by 46
Self-citationWhat Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 47
Gandini, A., Puglisi, S., Pirrone, C., Martelli, V., Catalano, F., Nardin, S., Seeber, A., Puccini, A., & Sciallero, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1161048 · Cited by 42
Das, S., Ciombor, K. K., Haraldsdottir, S., Pumpalova, Y., Sahin, I. H., Pineda, G., Shyr, Y., Lin, E. P., Hsu, C.-Y., Chu, S.-K., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0637 · Cited by 41
Kim, J. H., Seo, M.-K., Lee, J. A., Yoo, S., Oh, H. J., Kang, H., Cho, N., Bae, J. M., Kang, G. H., & Kim, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003414 · Cited by 45
Zhang, X., Yang, Z., An, Y., Liu, Y., Wei, Q., Xu, F., Yao, H., & Zhang, Z. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02549-7 · Cited by 42
Genomic instability as a driver and suppressor of anti-tumor immunity
Requesens, M., Foijer, F., Nijman, H. W., & de Bruyn, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462496 · Cited by 45
Bräunlein, E., & Krackhardt, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01702 · Cited by 43
Ma, Y., Fang, W., Zhang, Y., Yang, Y., Hong, S., Zhao, Y., Tendolkar, A. V., Chen, L., Xu, D. Z., Sheng, J., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0284 · Cited by 42
Tachon, G., Frouin, É., Karayan, L., Auriault, M., Godet, J., Moulin, V., Wang, Q., & Tougeron, D. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.01.087 · Cited by 42
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer
Thomas, J. V., Leal, A. D., & Overman, M. J. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.002 · Cited by 42
Self-citationRen, J., Xu, M., Chen, J., Ding, J., Wang, P., Huo, L., Li, F., & Liu, Z. (2020) · Theranostics · doi:10.7150/thno.45540 · Cited by 42
Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers
Yang, Y.-C. S. H., Ko, P.-J., Pan, Y.-S., Lin, H., Whang‐Peng, J., Davis, P. J., & Wang, K. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00719-5 · Cited by 46
Hou, J., He, Z., Liu, T., Chen, D., Wang, B., Wen, Q., & Zheng, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.755053 · Cited by 48
Saraf, A., Roberts, H. J., Wo, J. Y.-L., & Parikh, A. R. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7061 · Cited by 42
Horino, T., Tokunaga, R., Miyamoto, Y., Hiyoshi, Y., Akiyama, T., Daitoku, N., Sakamoto, Y., Yoshida, N., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12499 · Cited by 41
Merhi, M., Ahmad, F., Taib, N., Inchakalody, V. P., Shahab Uddin, M. S., Shablak, A., & Dermime, S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.001 · Cited by 41
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
Bhamidipati, D., & Subbiah, V. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.002 · Cited by 45
Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment
Lin, A., Ye, P., Li, Z., Jiang, A., Liu, Z., Cheng, Q., Zhang, J., & Luo, P. (2025) · Research · doi:10.34133/research.0723 · Cited by 44
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
Miura, Y., & Sunaga, N. (2018) · Cancers · doi:10.3390/cancers10080245 · Cited by 41
Zhao, B., Zhao, H., & Zhao, J. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0421-z · Cited by 43
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
Duchemann, B., Remón, J., Naigeon, M., Mezquita, L., Ferrara, R., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., et al. (2020) · Cancers · doi:10.3390/cancers12123625 · Cited by 42
Inoue, A., Robinson, F. S., Minelli, R., Tomihara, H., Rizi, B. S., Rose, J. L., Kodama, T., Srinivasan, S., Harris, A. L., Zuniga, A. M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.03.022 · Cited by 40
Self-citationThe therapeutic and prognostic implications of immunobiology in colorectal cancer: a review
Zaborowski, A. M., Winter, D. C., & Lynch, L. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01475-x · Cited by 40
Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
Zheng, Y., Fu, Y., Wang, P., & Ding, Z. (2022) · Disease Markers · doi:10.1155/2022/8270305 · Cited by 41
Telli, T. A., Bregni, G., Vanhooren, M., Saúde-Conde, R., Hendlisz, A., & Sclafani, F. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102460 · Cited by 43
Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1497-0 · Cited by 40
Self-citationAnghileri, E., Ianni, N. D., Paterra, R., Langella, T., Zhao, J., Eoli, M., Patanè, M., Pollo, B., Cuccarini, V., Iavarone, A., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02769-4 · Cited by 38
Zhou, J., Yu, L., Fan, Y., Guo, C.-H., Lv, X., Zhou, Z., Huang, H., Miao, D., Zhang, S., Li, X., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114860 · Cited by 41
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab
McQuade, J. L., Hammers, H. J., Furberg, H. F., Engert, A., André, T., Blumenschein, G. R., Tannir, N. M., Baron, A. D., Larkin, J., El-Khoueiry, A. B., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5409 · Cited by 40
Self-citationColle, R., Lonardi, S., Cachanado, M., Overman, M. J., Élez, E., Fakih, M., Corti, F., Jayachandran, P., Svrcek, M., Dardenne, A., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad082 · Cited by 41
Self-citationFeng, C., Li, Y., Tai, Y., Zhang, W., Wang, H., Lian, S., Jin-si-han, E.-E.-M.-B.-K., Liu, Y., Li, X., Chen, Q., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45558-6 · Cited by 42
Microsatellite instability and mismatch repair protein deficiency: equal predictive markers?
Nádorvári, M. L., Lotz, G., Kulka, J., Kiss, A., & Tı́már, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611719 · Cited by 40
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 43
Grizzi, F., Basso, G., Borroni, E. M., Cavalleri, T., Bianchi, P. P., Štifter, S., Chiriva‐Internati, M., Malesci, A., & Laghi, L. (2018) · Inflammation Research · doi:10.1007/s00011-017-1128-1 · Cited by 42
Winer, A., Ghatalia, P., Bubes, N., Anari, F. M., Varshavsky, A., Kasireddy, V., Liu, Y., & El‐Deiry, W. S. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0686 · Cited by 40
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
Mylvaganam, G., Yanez, A. G., Maus, M. V., & Walker, B. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02109 · Cited by 38
Histologic patterns of liver injury induced by anti-PD-1 therapy
Zhang, D., Hart, J. A. L., Ding, X., Zhang, X., Feely, M., Yassan, L. J., Alpert, L., Soldevila‐Pico, C., Zhang, X., Liu, X., et al. (2019) · Gastroenterology report · doi:10.1093/gastro/goz044 · Cited by 40
Endo, E., Okayama, H., Saito, K., Nakajima, S., Yamada, L., Ujiie, D., Kase, K., Fujita, S., Endo, H., Sakamoto, W., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0308 · Cited by 40
Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer
Xu, T., Zhang, Y., Zhang, J., Qi, C., Liu, D., Wang, Z., Li, Y., Ji, C., Li, J., Lin, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568911 · Cited by 40
Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
Fu, Y., Peng, Y., Zhao, S., Mou, J., Zeng, L., Jiang, X., Yang, C., Huang, C., Li, Y., Yin, L., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.689727 · Cited by 40
Metadata
- Authors
- Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., Goldberg, M. V., Cao, Z. A., Ledeine, J.-M., Maglinte, G. A., Kopetz, S., & André, T.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Trials Ireland (IE)
- Allina Health (US)
- Istituto Oncologico Veneto (IT)
- USC Norris Comprehensive Cancer Center (US)
- Duke Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Bristol-Myers Squibb (United States) (US)
- Bristol-Myers Squibb (Belgium) (BE)
- Sorbonne Université (FR)
- Corresponding author
- Overman, Michael J
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 18
- Issue
- 9
- Pages
- 1182-1191
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC6207072
- OpenAlex
- W2739132742
- Cited by
- 2,836
- References
- 37
- Citations by year
- 2026: 185 · 2025: 242 · 2024: 302 · 2023: 382 · 2022: 377 · 2021: 438 · 2020: 361 · 2019: 288 · 2018: 223 · 2017: 31
- FWCI
- 108.88
- Type
- journal article
- Language
- en
- Update notices
- erratum (2017-09-01)
- Open access
- green
- europepmc.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- National Institutes of Health (UL1TR000371)
- National Cancer Institute (P30CA016672)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- nivolumab, metastatic colorectal cancer, mismatch repair deficiency, microsatellite instability-high, PD-1 inhibitors, immune checkpoint blockade, objective response rate, disease control rate, progression-free survival, overall survival, treatment toxicity, first-line therapy, second-line therapy, third-line therapy, neoantigens, tumor-infiltrating lymphocytes
- MeSH terms
- Nivolumab, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Female, Humans, Male, Middle Aged, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Microsatellite Instability, DNA Mismatch Repair, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
